BFRG BullFrog AI Holdings, Inc.
Listings ·
Nasdaq gave BullFrog AI until February 8, 2027 to regain the $1.00 minimum bid price. Stockholders approved a reverse stock split at a ratio of not less than 1-to-2 and not more than 1-to-15.
We have not published a story on BullFrog AI Holdings yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $116,670 | |
| Research and development | $1.8 million | $2.2 million |
| Net income (loss) | -$6.5 million | -$7.0 million |
| Cash from operations | -$5.5 million | -$5.6 million |
| Cash and equivalents | $2.2 million | $5.4 million |
Our latest story on this, dated Aug 18, 2026: "BullFrog AI granted Nasdaq second compliance period for bid price". The story links the filing or release it is based on. Read the story.
BullFrog AI Holdings, Inc. trades under the ticker BFRG on NASDAQ.
BullFrog AI Holdings, Inc. is listed on NASDAQ.
Our directory records BullFrog AI Holdings, Inc. under United States.
aibio.space lists BullFrog AI Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$116,670 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
BullFrog AI Holdings, Inc. reported a net loss of $6.5 million for the fiscal year ended Dec 31, 2025, and used $5.5 million of cash in operations, per its annual report to the SEC.
$1.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$6.9 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on BullFrog AI Holdings, dated Aug 18, 2026: "BullFrog AI granted Nasdaq second compliance period for bid price". Nasdaq gave BullFrog AI until February 8, 2027 to regain the $1.00 minimum bid price. Stockholders approved a reverse stock split at a ratio of not less than 1-to-2 and not more than 1-to-15. Source.
Press Follow on this page to add BullFrog AI Holdings to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming BullFrog AI Holdings so far, in Listings.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio